The SIOPE Strategic Plan is one of the deliverables of the European Network for Cancer research in Children and Adolescents (ENC-CA), a network of excellence that was run from 2011 to 2015 under the EU 7th Framework Programme for research and innovation (FP7).
This plan was first elaborated by a dedicated working group, the ENCCA Long-term Sustainability (LTS) working group. Established within the ENCCA project, this group is composed of outstanding experts in paediatric oncology: Andrea Biondi, Angelika Eggert, Lars Hjorth, Jerzy Kowalczyk, Ruth Ladenstein, Giorgio Perilongo, Rob Pieters, Kathy Pritchard-Jones, Martin Schrappe, Richard Sullivan and Gilles Vassal (working group chair).
The first document has been presented, discussed, and refined through the contributions of SIOPE Board members and partners from the ENCCA project, the European Clinical Trial Groups (ECTGs) and the National Paediatric Haematology-Oncology Societies (NaPHOS)both parts of the European Clinical Research Council for Paediatric and Adolescent Oncology (CRC, formerly ECRC) -the ENCCA Parent Patient Advocacy Committee (PPAC), and the Europe Regional Committee of Childhood Cancer International (CCI).
On September 18 th and 19 th , 2014, SIOPE organized a conference in Brussels entitled 'Joining efforts for a brighter future for children and adolescents with cancer -The European roadmap to Horizon 2020', in order to ensure the sustainability on the long-term of the results achieved in the framework of ENCCA. On this occasion, approximately 160 participants from 31 countries -representing all stakeholders (patients, survivors, parents, academia, charities, industry, regulators, EU policy-makers) -endorsed the SIOPE proposal and called for a European Cancer Plan for Children and Adolescents.
The ENCCA Scientific Advisory Board (composed of Peter Adamson, Ulrik Ringborg, Holger Schünemann) reviewed the proposal in early 2015.
The pre-final draft was approved by the SI-OPE General Assembly in October 2014, by the ENCCA General Assembly in January 2015, and the final version has been approved by the SIOPE Board on May 20th, 2015.
The SIOPE Strategic Plan will be launched at the 2015 European Cancer Congress in Vienna in September 2015 and at the European Parliament during a special event of the Members of the Parliament Against Cancer (MAC) group in November 2015.
SIOPE will steer and coordinate the effective implementation of this Strategic Plan, together with the European Clinical Trial Groups (ECTGs) and the National Paediatric Haematology Oncology Societies (NAPHOS) in close cooperation with the parents, patients, and survivors' advocates from the Europe Regional Committee of Childhood Cancer International (CCI).
Cross-tumour platforms and projects will facilitate this implementation: a Clinical Trial Facilitating (CTF) platform to ease setting up of clinical trials within the new EU Clinical Trial Regulation, the PICORET (Population Improvement in Childhood cancer Outcomes through Research, Evaluation and Training) outcome research project to evaluate and monitor progress in childhood cancer survival and therapy effectiveness, the QUARTET (Quality and Excellence in Radiotherapy and Imaging for Children and Adolescents with Cancer across Europe in Clinical Trials) project for quality assurance in radiation therapy, the CDDF-SIOPE-ITCC multi-stakeholder platform to improve oncology drug development for children and adolescents, and the 'Ethics, Social Science and Humanities' project to address the ethical aspects related to paediatric cancer. An efficient IT infrastructure to support e-Health and research will be developed, and a European Reference Network for paediatric patients with cancer will be created to facilitate crossborder healthcare and access to expertise.
The 'Oncopolicy' programme will ensure that the needs of young people are well taken into account into all EU policy initiatives in the field of health and research. Finally, the 'Education and Training' programme will ensure an adequate training to paediatric oncology health professionals.
Partnerships will be strengthened with patients, parents and survivors' advocates, adult oncologists as well as paediatric oncologists from other continents. 'Intelligent and transparent' public-private partnerships, recognizing the specificities of paediatric haematology-oncology, will be established with industry. The Strategic Plan's projects and structures will be funded through European and national grants, as well as by charities and industry.
In conclusion, as a result of several initiatives to involve all stakeholders and ensure that all their points of view would be taken into account in the document, this long-term sustainable Strategic Plan has achieved a broad consensus, and will serve as a 'European Cancer Plan for Children and Adolescents'.
g Each year there are 35,000 new cases of cancer in children and adolescents in Europe (15,000 in children below the age of 15 years and 20,000 in those aged 15-24). g 1 out of 600 new-borns will develop cancer before turning 20. g 80% are disease-free after 5 years from diagnosis, thanks to the currently available multidisciplinary treatments:
h Today there are approximately 300,000 EU citizens surviving a childhood cancer. In 2020, they will be nearly half a million; h Two-thirds of survivors have late side effects of treatment, which are severe and impact on the daily life of half of those affected; h Beyond 5 years from diagnosis, disease-free survivors have higher mortality rates than their non-affected peers. g 6,000 young people die each year of cancer.
g Despite improving survival rates, cancer is still the first cause of death by disease beyond one year of age in the EU.
g Cancers in children differ from cancers in adults. The most frequent childhood cancers are leukaemias, tumours of the central nervous system (CNS), lymphomas and neuroblastomas. They occur from birth to adolescence, with 35% of the typical childhood cancers occurring before the age of five years.
g Considering epidemiology and outcomes, there are three main groups of paediatric cancers: h Those with a good prognosis (with a higher than 85% chance of survival after five years) under current standard multidisciplinary treatments, using cytotoxic drugs in often an intensive mode (acute lymphoblastic leukaemia, lymphomas, retinoblastoma and renal tumours). Over the last five years, the survival rates have plateaued for patients suffering from these malignancies, while treatment intensity has been reduced for some patients in order to decrease the risk of long-term sequelae;
Cancer in young people in Europe
Paediatric cancer is still a major public health issue, despite high survival rates compared to adult cancers Figure 1 : Proportion of the 12 main tumour groups in children and adolescents in Europe [1] h Those with a poor prognosis (~50% or less 5 year survival) such as acute myeloid leukaemia, several CNS tumours, neuroblastoma, bone and soft tissue sarcomas. Among these diseases, some have a very poor prognosis such as diffuse intrinsic pontine glioma, high-risk neuroblastoma and metastatic sarcomas;
h The extremely rare tumours, for which there is insufficient information on their real incidence and survival. [3] . Causes of deaths are classified according to the ICD-10 (WHO, 1992) g Five-year survival is generally 10 to 20% lower in Eastern Europe, a disparity that becomes even larger for cancers which already have poor outcomes [2] .
g There are already standards of care for paediatric oncology treatment centres [4] , but these are not applied equally across Europe [5] .
g Teenagers and Young Adults (TYA) aged 15 to 24 years have very specific needs which are not equally addressed across Europe and there are still differences in their 5 years survival when compared to younger children with the same malignancy.
Unequal access to standard care and research across Europe g Progress has been made over the last 50 years by using intensive chemotherapy regimens (combined with surgery and/or radiotherapy in solid tumours). This includes improved outcomes in some cancers with poor prognosis such as high-risk neuroblastoma (40% survival with highly intensive chemotherapy regimens including immunotherapy) and acute myeloid leukaemia (60% survival with intensive chemotherapy and allogeneic hematopoietic stem cell transplantation).
g Patient survival has plateaued over the last five years or more for difficult-to-treat diseases, which calls for innovative treatments with new mechanisms of action to control resilient and resistant diseases.
There has been little progress regarding difficult-to-treat diseases during the last five years g Care and research are well integrated on a daily basis, and many high-level basic and translational research teams are dedicated to paediatric malignancies.
g Approximately 350 European public specialised centres in paediatric university hospitals and comprehensive cancer centres take care of patients with a paediatric cancer, and private practice is extremely rare.
g There is a strong awareness of the needs and challenges for childhood cancer survivors, with dedicated groups (e.g. PanCare, the Pan-European network for Care of survivors after childhood and adolescent cancer) encompassing both healthcare professionals and survivors.
g Most clinical trials are run at the European level for each malignancy by well-organized European Clinical Trial Groups (ECTGs).
g Up to 90% of newly diagnosed patients are treated according to standard protocols or in prospective clinical trials. Up to 40% of patients are treated within therapeutic trials, both at diagnosis or at relapse, and clinical research is mainly led by academia, with industry-sponsored trials representing less than 5% of biomedical research.
g The paediatric haematology-oncology community is accustomed to working together since more than 50 years, with a strong track record of publishing peer reviewed research.
Though the area of paediatric haematologyoncology is small, it is extremely complex and covers at least 60 different types of cancer in a population ranging from newborns to teenagers, and even more when biological markers ("biomarkers") are considered [6] .
Strengths

Paediatric haematology-oncology in Europe
Credit Israel Society of Pediatric Hematology and Oncology (ISPHO), Israel g There is a lack of sustained and sufficient funding, with high levels of competition for funding and need for prioritisation. g There are considerable disparities in Europe in the implementation of research (clinical, translational and basic) and in access to standard care, in particular for TYA.
g Paediatric haematology-oncology is not recognised as a sub-specialty in most countries.
g Parents, patients and survivors' organisations lack tools and platforms to better join forces with all stakeholders.
g A certain level of fragmentation of research remains, in spite of a long history of networking and major efforts to build together a common infrastructure.
g Paediatric haematology-oncology has grown and achieved successes so far in relative isolation in comparison with the adult oncology community.
Weaknesses g The availability of high-throughput technologies that can quickly deal with large numbers of samples will allow new breakthroughs in understanding paediatric tumour biology. Opportunities g There has been a strong commitment by the Members of the European Parliament to support the paediatric haematology-oncology agenda, for instance via their endorsement of the SIOPE-ENCCA-ICCCPO Manifesto for Paediatric Oncology.
g Advocacy groups of parents, patients and survivors advocates are increasingly well organized in Europe (through Childhood Cancer International (CCI), formerly ICCCPO) and are strongly committed and equal partners in the European care and research agenda.
g Charities in several countries are committed to support and finance research programmes on cancer in children and teenagers.
g There is a possibility that due to factors such as a high cure rates, decision-making leaders at the European and national levels might consider that paediatric cancer is not a priority, supposing that all efforts should be concentrated only on cancer prevention in adults and on transforming cancer into a controlled chronic disease in the ageing population.
g The global economic crisis hindered the capacity of several EU Member States to improve their healthcare system to deliver standard treatments for young people with cancer.
g There is limited access to some essential medicines, due to drug shortages and to the high price of new medicines.
g Issues around the lack of collection of data in patients with diseases that have a good prognosis under standard treatment mean that the quality of care and, eventually, the probability of cure will be decreased.
g Wide-ranging EU regulatory initiatives might negatively impact the implementation of the goals of the paediatric haematology-oncology community, for example the EU General Data Protection Regulation (2012/0011(COD)) under discussion at the time of publication could impact on research and trials.
Threats
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From AIEOP. Credit Attilio Rossetti photographer, Italy "The needs of children with cancer have not been high on the political radar" (Richard Sullivan, UK) g To increase the cure rate for young people who have a cancer with a poor prognosis.
g To increase the quality of life for survivors of childhood cancer.
The measure of success will be 10 years free of disease and late side effects.
The seven objectives (with equal importance and weight) The overall goals over the next 10 years
Overall goals and objectives
Key success factors to achieve these objectives g Both at the European and national levels, there is a need for better integration, coordination and improved long-term sustainability of research. This is especially true when EU funding is more fragmented.
g Commitment from all funding bodies to fund projects and structures relevant to these objectives (including the European Commission, national funding bodies, charities, industry, and investors).
g The profile of paediatric haematology-oncology in the European cancer agenda should be strengthened, and its visibility increased through a more efficient communication strategy.
g A strong partnership with parents, patients and survivors, including better communication and dissemination of information.
g Levels of collaboration with adult oncology should be improved.
g Being part of the global paediatric oncology agenda and developing further collaborations with other continents.
g Building intelligent and transparent partnerships with industry.
g Effective and appropriate European regulations are vital and must be encouraged and engaged with.
Objective 1: Innovative treatments
To introduce safe and effective innovative treatments (i.e. new drugs, new technologies) into standard care.
Innovative oncology drugs with new mechanisms of action (MOA) are already available for adult cancers, and can be more effective than traditional drugs in several refractory malignancies.
The field of drug development is currently expanding beyond well-studied areas like signalling pathways, to target patient's immune system, as well as their unique genetic profile and metabolism. Despite recent EU regulatory initiatives that changed the landscape of paediatric drug development in Europe for the better, access of children and adolescents with cancer to innovative therapies remains insufficient and slow [7] .
Strategy
g To develop and deliver a new drug development strategy -by disease and across diseases -based on the specific biology of patients' tumour, taking into account existing therapeutic strategies implemented by the ECTGs;
g To provide a guide for efficient and innovative public-private partnerships between academia and the pharmaceutical industry, within the frame of the EU Paediatric Medicine Regulation.
Actions
1. Across Europe, increase the access of patients to new and innovative therapies, including better referral of patients, and install a molecular and immunological tumour portrait as a standard of care at the time of relapse as well as at diagnosis for patients with a highrisk and resistant diseases (link with objective 2); 2. Improve the evaluation of adult cancer drugs for use in the paediatric population, establishing a clear drugs' prioritisation and avoiding unjustified waivers (not allowing an adult drug to be translated to children);
3. Identify targets in paediatric cancers and, thus, develop specific paediatric anti-cancer drugs (link with objective 3);
Develop innovative technologies such a high precision radiation therapy and interventional radiology;
5. Develop innovative designs and methods for efficient studies, both in early phase and phase III clinical trials;
6. Influence changes in the relevant regulations;
7. Develop international academic collaboration and efficient cooperation with main stakeholders (patients, survivors, parents, academia, charities, industry, regulators, EU decision-and policy-makers).
The European new drug development programme will be implemented by the European consortium for Innovative Therapies for Children with Cancer (ITCC), in collaboration with the disease-specific European Clinical Trials Groups (ECTGs).
Brought about by ENCCA, the CDDF (Cancer Drug Development Forum)-SIOPE -ITCC paediatric oncology platform was created in 2013 with academia, industry, parents and regulators in order to make proposals for improving new oncology drugs development for children and adolescents [8] .
Risk stratification is used in paediatric haematology-oncology to adapt the intensity of patients' treatment to their own individual risk of failure. It is part of standard of care, is based on the extent of the disease and, increasingly, on tumour biology and response (e.g. in neuroblastoma and leukaemias) [9] [10] [11] . There has been recent progress in the classification of severalpaediatric malignancies (such as medulloblastoma, high grade glioma, ependymoma and rhabdomyosarcoma) based on specific aspects of their biology [12] . This will lead to new "biomarkers" that can be used in clinical practice to improve risk stratification and to better adapt existing and new treatments (objective 1) to each patient.
Objective 2: Precision cancer medicine
To use improved risk classification as well as biological characteristics of both the tumour and patient (such as molecular and immunological factors) to help guide decisions on which therapies to use.
Strategy g To analyse the specific biology (molecular profiling) of both the patient and tumour at the point of diagnosis and throughout treatment to improve risk stratification for adapted individual treatment by identifying:
h Patients with a high probability of cure with standard treatment, who may be proposed new or reduced interventions to decrease the risk of late effects; h Patients with a poor prognosis tumour to whom innovative therapies should be proposed as early as possible, to increase their probability of cure.
Actions
1. Run prospective clinical trials with innovative design and methods to confirm the use of biomarkers and algorithms in risk stratification, treatment allocation and disease monitoring;
2. Enhance the collaboration between specialists such as biostatisticians, clinicians and biologists;
3. Expand the availability and accessibility of biomarkers for clinical and research use by setting up a network of the necessary molecular laboratories;
Objective 3: Tumour biology
To increase knowledge of tumour biology and speed up translation from basic research to clinical care to benefit patients.
Cancers in adults result from processes that have multiple steps, mainly following exposure to external carcinogens (tobacco, alcohol, UV, diet, etc.) and often progression over many years.
In contrast, paediatric cancers develop early in life and over a much shorter time period, suggesting that fewer and stronger events are required for progression. They are rare, and most show fewer genetic defects and a lower genetic complexity as compared to adult cancers [13] .
Major progress has been made in understanding paediatric tumour biology, leading to the discovery of unique cancer hallmarks that are also involved in cancer formation in adults, such as the RB1 gene in retinoblastoma and, more recently, Histones H3 mutations in diffuse intrinsic pontine gliomas [12] . These advances have already resulted in new classification of several diseases. Additionally, the role of the immune system in controlling tumour growth is now well-established in many adult cancers, and the challenge is to translate this new findings into successful therapies.
Strategy
g To use modern and innovative technologies to further uncover the mechanisms of paediatric tumour development, progression and relapse. Also, to explore the genetic and cellular heterogeneity within the same tumour, the regulation of genes (epigenetics), and the role of the immune system, metabolism and the tumour's own surroundings (micro-environment); 4. Develop research in functional imaging, set up a European imaging platform as well as a platform for quality control in radiation therapy;
5. Improve data sharing, especially those that are linked, such as genomic and clinical data, and widen access of such information to researchers;
6. Facilitate international academia-led clinical trials (via facilitated submission processes, shortening the time needed from conception to launch); 7. Widen access to tumour samples and nucleic acids for researchers.
This strategy will be implemented by the ECTGs developing research in each paediatric malignancy, and it will be facilitated by the cross-tumour European platforms and programmes set up within SIOPE.
Credit Czech Working Group for Paediatric Oncology, Czech Republic
Objective 4: Equal access
To bring about equal access across Europe to standard care (in both diagnosis and treatment), expertise and clinical research.
Treating children with cancer is a complex matter, and needs the expertise of a highly specialised multidisciplinary team. Across Europe, there is a 10 to 20% difference in 5 year survival, between countries with population-based cancer registrationthe differences may be much greater where no such outcome data currently exist. SIOPE led the preparation, definition and dissemination of the 'European Standards of Care for Children with Cancer', and a recent SIOPE survey within the European Partnership for Action Against Cancer (EPAAC) showed that there is a wide disparity in the implementation of these standards of care across different European countries [4] . h Create tumour boards by disease -to be considered at three levels: institutional, national and European -in order to provide advice on the best appropriate treatment and care for individual patients;
h Identify centres that are able to deliver standard care and treatments (specialist centres) as well as hubs of coordination, which will also deliver complex treatments and specialised technology;
h Improve referral to specialist centres and hubs of coordination within EU member states and across borders; h Set up an efficient e-Health and IT platform;
2. Warrant availability of essential medicines for all patients;
3. Specifically address the needs of children and adolescents with extremely rare cancers (e.g. adult cancers such as thyroid cancer, breast cancer and melanoma -occurring extremely rarely in the paediatric population -and extremely rare specific paediatric malignancies such as pleuropulmonary blastoma, etc.); 4. Ensure that paediatric cancer registries cover all European countries, in order to adequately monitor the effects of the present Strategic Plan, and ensure that each National Cancer Plan addresses the specific needs of children and adolescents with cancer;
5. Significantly improve access to palliative care for young patients at the end of their lives;
6. Provide high quality training for all health professionals across Europe, and make paediatric haematology-oncology a recognised sub-specialty.
The ExPO-r-Net project, funded by DG SANTE, is currently piloting the concept of a European Reference Network (ERN) in paediatric haematology-oncology, which specifically addresses the topic of extremely rare cancers and long-term follow-up. 
Objective 5: Teenagers and Young Adults
To address the specific needs of teenagers and young adults (TYA), in cooperation with adult oncology.
Although cancer in teenagers and young adults is rare, it is a substantial cause of death in this population. Outcomes are often poorer than in younger patients with the same cancer, and several contributory factors have been identified: the type of tumours, their biology and sensitivity to current therapies, as well as the low participation of TYA in clinical trials [14] [15] . TYA have specific and unmet needs, including complex psychological and social supportive care. Their position between adult and children's services in healthcare systems does not allow for the best possible provision of care or dedicated research that could improve their quality of survival.
Strategy
g To develop a comprehensive multidisciplinary European programme, tackling all issues and specific needs of the TYA population. This will be a joint integrated programme between paediatric and adult oncology, in strong partnership with patients. Within ENCCA a pilot project has been initiated in order to build the European Network for Teenagers and Young Adults Cancer [14] .
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From AIEOP. Credit Attilio Rossetti photographer, Italy
Objective 6: Quality of survivorship
To address the consequences of cancer treatment such as long-term side effects, to better understand the genetic background/ risk of an individual, and to improve quality of life of survivors of childhood cancer.
With an 80% survival at five years, the number of childhood cancer survivors (currently estimated to be more than 300,000 in Europe) is likely to continue to increase, and improving their quality of life is a major goal. Two-thirds of survivors have late-occurring side effects due to their treatments, which are severe in half of them, and have a strong impact on their daily lives. It is anticipated that in 2030 there will be around 750,000 paediatric cancer survivors in Europe.
The PanCare network was created in 2008 to address this issue [16] . PanCare is a pan-European multidisciplinary network of health professionals, survivors of paediatric cancer and their families, who collaborate to reduce the frequency, severity and impact of late treatment side effects, with the aim of ensuring that every survivor of childhood cancer receives the best possible long-term care. In addition, several survivors' associations were created recently to empower survivors and to help them tackle the issues raised above.
Strategy
g To improve awareness of the needs of childhood cancer survivors, together with them, and facilitate research on it;
g To empower survivors to take the responsibility for their own follow-up, ensuring that they are well-informed on what to be aware of, how and when to access care and follow-up, and who to turn to if and when they need to;
g To encourage health organisations to address the issues of long-term follow-up and ease the transition to adult medicine;
Objective 7: Causes of cancer
To understand the causes of paediatric cancers and to address prevention wherever possible. 5. Anticipate long-term toxicities of innovative therapies, such as targeted therapies, that will be introduced in standard treatments;
Two ongoing FP7 European projects, PanCareSurFup and PanCareLIFE, carry out research on late-occurring side effects [17] . The pilot initiative of the 'Survivorship Passport' is being developed thanks to the support of ENCCA and PanCareSurFup, and the organisation of care including a virtual late-effects advisory centre, will be also addressed within the ExPO-r-NET project.
It is estimated that 4-8% of paediatric cancers occur within a known genetic predisposition and more than 100 genetic syndromes with a risk of cancer in childhood are known. The proportion may increase as more and more rare cancer gene mutations are discovered through ongoing analyses in areas such as genomics. Some studies already suggest that up to one in four children and adolescents with a history of cancer may have a genetic predisposition condition [18] . The identification of the genetic basis of rare inherited cancers in children has revealed key pathways that are shared with sporadic tumours, even in adults.
Sequencing of the whole genome will generate new information that can be used to improve care and to identify new genetic hallmarks of cancer, which can be turned into targets for new therapies.
Strategy
g To increase research focused on predisposition to childhood cancer and on the oncogenic drivers that increase the risk of childhood cancer by:
h Using whole genome sequencing to further uncover genetic predisposition to paediatric cancers;
h Carefully addressing the pragmatic and ethical issues of genetic testing and counselling, anticipating that DNA testing is becoming widely available;
h Addressing questions on the environmental causes of paediatric cancer through scientifically-led and evidence-based studies. In 2008, funding for paediatric oncology research was estimated, using previously validated econometric analysis of research activity [20] , to be 1,229 USD millions, with more than 50% from public funding, including international funding such as European framework funding and just under 20% from the pharmaceutical industry [21] . In 2013, this has been estimated to have dropped to 900 USD millions, a decline over 25% over five years.
Research output is growing, particularly in clinical research, but availability of short-term funding is getting worse despite more European programmes. In addition, most of the public policy discourse has been focused on an ageing European society and the needs of children with cancer are not high on the political radar, despite the fact that cancer is the leading cause of death by disease in the young population. Globally, childhood cancer is being heavily marginalised.
The SIOPE objectives are: g To improve public, political and policy visibility of childhood cancer research; g To show the existing linkage between research activity and better outcomes for children with cancer in Europe;
g To develop strategies in order to broaden research engagement;
g To address both pan-European research funding and national funding streams, as well as funding from charities.
Childhood cancer from a societal perspective 
Clinical epidemiology platform for outcome research -The PICORET project
The Population Improvement in Childhood Cancer Outcomes through Research, Evaluation and Training project (PICORET) will address the needs of clinical epidemiology and outcome research in paediatric haematologyoncology. Several paediatric cancers have a high survival rate with treatments that have been established through prospective European randomised trials. Populationbased cancer registries measure overall but not relapse-free survival, and so there isn't sufficient information on the effectiveness of first line therapy at a population level.
PICORET will monitor the survival of all children and adolescents with cancer in Europe and evaluate progress across Europe using information from registries and observational studies that use standard treatments. Such 'non-interventional' clinical studies can assess effectiveness of biomarkers, which can be used for prognosis, and allow analysis of traditionally hard-toresearch areas, such as surgical and imaging techniques. Through building enhanced clinical registry capabilities, PICORET will prospectively collect detailed clinical and biological information that can be used for quality improvement of diagnostics and treatment pathways for patients treated by a standard treatment outside of clinical trials. PICORET will monitor the survival of all children and adolescents with cancer in Europe, and will evaluate and compare the quality and effectiveness of treatments. High resolution studies will be run.
Initially, PICORET will focus on renal tumours, neuroblastoma and medulloblastoma as its first exemplars. It will develop standardised clinical guidelines as well as a standardisation and quality programme in standard care, with a special focus on infant dosing. Twinning between institutions in countries with higher and lower survival rates will be introduced. Data privacy will be carefully monitored, and the project's impact will be assessed.
Platform for quality assurance in radiotherapy -The QUARTET project
Quality assurance and quality control are mandatory when patients receive radiation therapy. This is to make sure that each patient gets the best treatment in terms of maximising effectiveness and minimising long-term side effects. However, they are not systematically performed within clinical trials and various programmes are implemented only in a limited number of EU countries.
The QUARTET project ('QUAlity and excellence in RadioTherapy and imaging for children and adolescents with cancer across Europe in clinical Trials') aims to build a radiation therapy quality assurance programme across all paediatric malignancies. It will be run in partnership with the European Organisation for Research on Treatment of Cancer (EORTC) and Aquilab for patients participating in clinical trials using radiation therapy and run by ECTGs. Eventually, the platform will expand its activity to patients treated outside of clinical trials.
Multi-stakeholder platform for new paediatric oncology drug development -The CDDF-SIOPE-ITCC platform
This multi-stakeholder platform was created in December 2013 by Cancer Drug Development Forum (CDDF), SIOPE and ITCC as a deliverable of the ENCCA project to improve oncology drug development for children and adolescents [8] . Academia, parents and survivors, industry and regulators are equally represented and work together on the following objectives:
g To set up drug prioritisation and enable drug development, based on the mechanism of action of the drug as well as biological factors;
g To propose changes in the EU Paediatric Medicine Regulation to better address the needs of those with life threatening diseases;
g To propose new incentives for the development of specific paediatric drugs and repurposing of existing drugs;
g To implement long-term follow up measures for new oncology drugs for children and adolescents.
Ethics, Social Sciences and Humanities programme
This is a natural development of the ethics programme set-up within ENCCA to maintain and improve the level of expertise on ethics in the field of paediatric cancer care and research. It is based on two priorities, namely to reflect the multidisciplinary nature of social sciences and humanities where suitable to paediatric oncology, and to facilitate access to appropriate expert views from professionals and from patients' representatives on ethical issues.
Following these priorities, "ethics" is meant as a multidisciplinary approach to the non-technical issues related to the care, protection, and self-realisation of paediatric oncology-haematology patients (or former patients). It is proposed to develop a nonprescriptive, participatory and outcomesoriented approach to these issues, harnessing the relevant knowledge and expertise in the Social Sciences and Humanities (SSH) field.
Four main topics will be addressed by this programme: i) return of research results, ii) personal data in care and research environments, iii) access to medical innovation, iv) care and healthcare pathways. The programme will be performed through objective assessment of the non-technical issues related to the care and quality of survival of children and adolescents with cancer, as well as through community-based participatory research actions within the paediatric oncology community.
In accordance with the successful implementation within ENCCA, the programme will be steered and run by a permanent contact point along with ad-hoc academic collaborations. A steering Legal and Ethical Advisory Board will peer-review the projects and the results. The following tools will be set up: i) a thematic database of ethics expertise in Europe, identifying expert individuals and centres in Western and Eastern European Universities, ii) a database of local initiatives for bedside and benchside ethics, accessible to professionals and patients, iii) an initiative to establish multi-centre collaborations on nontechnical interventions (fostering experiencesharingand multicentre evaluation).
All this is expected to generate sustained community dialogue, concerted evidence generation as well as transverse capacitybuilding on non-technical domains, first of all on ethical issues.
The SIOPE portal
The portal set-up within the ENCCA project will be transferred to SIOPE after the end of the ENCCA project (December 2015) . This online 'one-stop-shop' portal will support communication and interaction between everyone involved in implementing the strategic research agenda. It will serve as a resource for documentation and as a platform for information exchange.
Each patient will have a unique ID (EUPID) so that their data can be anonymised and shared between different databases. A pilot project for an integrated IT structure that will allow information to be linked between sources (such as registries, clinical trial databases, hospital electronic health records) and users (such as researchers and analysts) is being developed by the IT providers of ENCCA.
Within ENCCA, a consultation IT platform has been developed for patients with haepatoblastoma (a very rare disease) by SIOPEL along with CINECA. This platform (including pathology slides and images) facilitates access to expert advice for diagnosis and treatment, including indications of liver transplant. This IT tool is further developed within the ExPO-r-Net project for retinoblastoma and extremely rare paediatric tumours, and will eventually be adapted for other diseases within the Paediatric Oncology Europe Reference Network.
In addition, an IT platform for virtual tumour boards will be developed.
Based on these experiences and following those pilot projects, SIOPE and ECTGs will define how to structure the best IT environment that will allow the implementation of the Strategic Plan.
Network of biobanks
Samples from patients and tumours, which are labelled with additional clinical information, are vital for the success of the SIOPE Strategic Plan. The aim of SIOPE is therefore to support a network of biobanks that can share data electronically, in keeping with EU data protection laws. The difficulty of the task is not underestimated.
A vital step in the development of such a network within SIOPE is the introduction of a unique patient identifier (the above mentioned EUPID) for every paediatric cancer patient treated in Europe, as well as the development of standardised patient consent forms. These must be in line with national data protection laws in European countries, and allow for new developments in molecular analysis of tumour samples (particularly nextgeneration sequencing), as well as the wishes of patients and parents and other ethical considerations.
In addition to this, ENCCA guidelines are currently being finalised on the standards for tumour and other patient samples (e.g. blood and plasma) as well as related materials like DNA and RNA, and on the process of access and use.
Oncopolicy programme
Several regulatory initiatives are of direct concern to paediatric haematologyoncology and the implementation of the SIOPE Strategic Plan. SIOPE has developed expertise and skills to monitor and influence the development of relevant European cancer health and research policy themes, and to ensure that the needs of the paediatric haematology-oncology community are taken into account when regulations are drafted or revised:
g Each National Cancer Plan should address the needs of children and adolescents with cancer, according to the European Cancer Plan. 
Training and education programme
The aim of this programme is to encourage high quality clinical and basic research as well as the delivery of high quality care in paediatric oncology throughout Europe. This is a remit of SIOPE and focuses on the organisation of educational courses and on the revision of the training syllabus in paediatric oncology.
SIOPE is involved in several training courses to develop the knowledge of health professionals on new and state-of-the-art therapies and allow them to gain more practical skills in the treatment of paediatric malignancies: SIOPE and the CCI Europe Regional Committee entered into a co-operative relationship in order to implement the European long-term Strategic Plan and to raise awareness on cancer in children and adolescents. They signed a Memorandum of Understanding that sets out the specific areas of cooperation along with the principles by which both parties will run the partnership. The four areas are: i) ethics and social sciences and humanities, ii) access to standard of care and expertise, iii) improvements to the regulatory and political environment at the pan-European and national level, iv) research and development.
Partnerships
Partnership with adult oncology
During the last 50 years, paediatric oncology has developed in relative isolation. Improving the cooperation of all paediatric haematologists and oncologists was the crucial objective so that an effective European clinical research programme could be set up and address the very specific needs of children with cancers without reference to adult cancer services.
It is now recognised that adult and paediatric oncology have a lot to share and learn from each other, and that collaboration is beneficial in order to address common goals and challenges:
g Care and research for rare cancers, in terms of innovative methodology to evaluate new treatments and in terms of health care organisation models to provide access to expertise for patients suffering from rare and extremely rare cancers;
g Care and research for TYA (see above);
g Access to essential medicines, since most anti-cancer drugs are used to treat both adult and paediatric cancers, even though there are differences in the tumours; Groups such as the SIOP-Renal Tumours Study Group support clinical trials groups in other continents that run studies using the same standard treatment backbones, adapted to local circumstances.
The COG and the European Inter-group for Childhood non Hodgkin lymphoma (EICNHL) are currently running a randomised phase III clinical trial to evaluate the addition of rituximab, an anti CD20 monoclonal antibody, on standard intensive chemotherapy treatment in high-risk Burkitt's lymphoma.
The European and American Osteosarcoma Study Group (EURAMOS) has successfully completed a large phase III study with partners, which included the COG, the European Osteosarcoma Intergroup, the Cooperative Osteosarcoma Study Group, and the Scandinavian Sarcoma Group. The EURAMOS Strategy Group, made up of these four multi-national groups, as well as the relevant Australasian, French, Italian, Japanese, and Spanish osteosarcoma groups, is exploring options for collaboration on an even larger platform.
In the next 10 years, international cooperation will be reinforced to evaluate innovative targeted drugs within extremely small and rare groups (defined by biomarkers), such as children with B-RAF mutated malignancies. Even in less rare clinical situations, international randomised clinical trials will be considered more regularly to speed up evaluation of innovative therapies.
Partnership with industry
For the last 50 years, progress has been made in curing paediatric cancers by running academic trials using anti-cancer drugs that are available in hospital pharmacy departments. Pharmaceutical companies have not developed their anti-cancer agents in the paediatric population, and nearly half of drugs used daily to cure cancer in children and adolescents do not have the regulatory official authorisation, stated in the 'Summary of Product Characteristics'.
In Europe this situation has significantly changed over the last five years because regulatory initiatives, first in the U.S. and then in Europe, obliged pharmaceutical companies to test their drugs in the paediatric population when relevant.
There was indeed an urgent need to access new drugs developed by pharmaceutical companies as early as possible during their development in adults, and to avoid families moving to the US to get access to innovative therapies in development.
Thanks to the EU Paediatric Medicine Regulation, pharmaceutical companies and academia have started to work together, to evaluate oncology drugs within paediatric investigation plans. This is a learning curve for everyone since pharmaceutical companies are not accustomed to working with paediatric oncologists and vice versa.
The goal is to develop 'intelligent and transparent' partnerships that recognise the specificities of paediatric haematologyoncology, i.e. a well-structured arena for clinical research, dealing with rare and complex situations, while the paediatric development of oncology drugs is, by definition, a pre-competitive research activity for pharmaceutical companies and competition to access rare patients makes no sense.
A new model of cooperation between pharmaceutical companies, academia and public-private partnership needs to be developed in order to adequately address the needs of children and adolescents with cancer and regulatory requirements. This is being addressed in the CDDF-SIOPE-ITCC paediatric oncology platform. In addition, a strategy will be implemented to encourage investment and partnership with small pharmaceutical companies to develop drugs against specific paediatric targets.
Partnership with charities
In several EU Member States, charities are extremely efficient at fundraising to support research and care for children and adolescents with cancer. These efforts are developed at the national level and can be fragmented, with significant differences between countries.
Most research programmes are run at the European level, and there is a need to figure out how charities from different countries can be more efficient at jointly funding large and ambitious European programmes.
SIOPE will propose to charities to fund and co-fund European projects and programmes. By defining, implementing and coordinating a long term sustainable Strategic Plan, SIOPE and the European paediatric haematology-oncology are willing to provide a transparent and clear visibility to the projects that will be run within a welldefined and integrated framework.
By definition, funding of the now established European strategy in paediatric haematologyoncology will come necessarily from several sources: the European Commission, national funding bodies, charities and foundations, industry as well as anyone willing to invest in paediatric oncology research and development.
European funding is available for research projects through Horizon 2020 calls. Projects in paediatric haematology oncology will be submitted to relevant European calls by SIOPE, groups and institutions as part of the implementation of the SIOPE Strategic Plan and referred as such in their application.
The critical hurdle encountered in paediatric haematology-oncology, as well as in other research areas, is the lack of funding for structures that are needed to run a coordinated and integrated research agenda. To this extent, in 2011 the European Commission provided €12m to structure oncology research into children and adolescents. One of the best examples of the goals achieved is the long-term sustainable Strategic Plan described in this document. ENCCA illustrates how funding for a permanent structure is essential to achieve progress and deliver success.
ENCCA will finish on December 2015 and the decision was taken that SIOPE will run the on-going agenda. The key question is how to fund the projects, the programmes and the structures that are needed to implement the long-term sustainable strategy.
At the end of the SIOPE-ENCCA event, which shared the European Strategic Plan with all stakeholders in Brussels in September 2014, the participants proposed to develop a European Cancer Plan for Children and Adolescents. This plan would show the commitment of the EU and its Member States to address childhood and adolescent cancers as a priority and a strategic objective for the European Union. Specific European initiatives would be set up to join efforts from the EU and its Member States for funding. In addition, it would allow other co-funding bodies to contribute to a pan-European initiative. 
